{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:44:16Z","timestamp":1783536256695,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.transci.2025.104183","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T19:58:21Z","timestamp":1750967901000},"page":"104183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A comparison of cyclophosphamide at different dose levels for stem cell mobilization in multiple myeloma"],"prefix":"10.1016","volume":"64","author":[{"given":"Abdullah","family":"Karakus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"Hatipoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavuz","family":"Katircilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali","family":"Erkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seda","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulsum Akgun","family":"Cagliyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahir","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine","family":"Hidayet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"Demircioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Koroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant","family":"Uzay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkadir","family":"Basturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleyman Sami","family":"Karti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Sarici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Servihan","family":"Unal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Sinan","family":"Dal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turgay","family":"Ula\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdal","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fevzi","family":"Altuntas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.transci.2025.104183_bib1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.transci.2025.104183_bib2","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.bbmt.2020.08.018","article-title":"The global state of hematopoietic cell transplantation for multiple myeloma: an analysis of the worldwide network of blood and marrow transplantation database and the global burden of disease study","volume":"26","author":"Cowan","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"10.1016\/j.transci.2025.104183_bib3","doi-asserted-by":"crossref","first-page":"772.e1","DOI":"10.1016\/j.jtct.2024.06.001","article-title":"Trends in outcomes after upfront autologous transplant for multiple myeloma over three decades","volume":"30","author":"Pasvolsky","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"7","key":"10.1016\/j.transci.2025.104183_bib4","doi-asserted-by":"crossref","first-page":"590.e1","DOI":"10.1016\/j.jtct.2021.04.016","article-title":"Stem cell mobilization in multiple myeloma: comparing safety and efficacy of cyclophosphamide +\/- plerixafor versus granulocyte colony-stimulating factor +\/- plerixafor in the lenalidomide era","volume":"27","author":"Johnsrud","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"5","key":"10.1016\/j.transci.2025.104183_bib5","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/bmt.2010.320","article-title":"Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens","volume":"46","author":"Jantunen","year":"2011","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"10.1016\/j.transci.2025.104183_bib6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Determination investigators. Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.transci.2025.104183_bib7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/jca.21421","article-title":"Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma","volume":"31","author":"Lin","year":"2016","journal-title":"J Clin Apher"},{"issue":"5","key":"10.1016\/j.transci.2025.104183_bib8","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00277-023-05170-0","article-title":"Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments","volume":"102","author":"Wei","year":"2023","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.transci.2025.104183_bib9","doi-asserted-by":"crossref","first-page":"244.e1","DOI":"10.1016\/j.jtct.2020.12.009","article-title":"Low-dose cyclophosphamide versus intermediate-high-dose cyclophosphamide versus granulocyte colony-stimulating factor alone for stem cell mobilization in multiple myeloma in the era of novel agents: a multicenter retrospective study","volume":"27","author":"Zannetti","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"8","key":"10.1016\/j.transci.2025.104183_bib10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.bmt.1702879","article-title":"A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients","volume":"27","author":"Fitoussi","year":"2001","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"10.1016\/j.transci.2025.104183_bib11","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s00432-016-2270-9","article-title":"Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients","volume":"142","author":"Winkelmann","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"10.1016\/j.transci.2025.104183_bib12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/sj.bmt.1703840","article-title":"Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma","volume":"31","author":"Jantunen","year":"2003","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"10.1016\/j.transci.2025.104183_bib13","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jca.21283","article-title":"Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma","volume":"28","author":"Shimura","year":"2013","journal-title":"J Clin Apher"},{"issue":"7","key":"10.1016\/j.transci.2025.104183_bib14","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.bbmt.2012.01.005","article-title":"Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies","volume":"18","author":"Hamadani","year":"2012","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"10.1016\/j.transci.2025.104183_bib15","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/ejh.13693","article-title":"Safety of outpatient stem cell mobilization with low- or intermediate-dose cyclophosphamide in newly diagnosed multiple myeloma patients","volume":"107","author":"Pompa","year":"2021","journal-title":"Eur J Haematol"},{"issue":"Suppl","key":"10.1016\/j.transci.2025.104183_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.HS9.0000936236.83735.8b","article-title":"High dose cyclophosphamide as mobilization regimen in newly diagnosed multiple myeloma: safety and efficacy in an outpatient setting. Single center experience","volume":"7","author":"Massarotti","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.transci.2025.104183_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2024.102111","article-title":"Apheresis product total CD34+ cell count prediction at peripheral stem cell collection via a formula: a multicenter study","volume":"86","author":"Yildirim","year":"2024","journal-title":"Transpl Immunol"},{"issue":"5","key":"10.1016\/j.transci.2025.104183_bib18","first-page":"691","article-title":"Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g\/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma","volume":"17","author":"Goldschmidt","year":"1996","journal-title":"Bone Marrow Transpl"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147305022500120X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147305022500120X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T10:18:44Z","timestamp":1753352324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147305022500120X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S147305022500120X"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2025.104183","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparison of cyclophosphamide at different dose levels for stem cell mobilization in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2025.104183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104183"}}